24-h Efficacy of Glaucoma Treatment Options

Basit Öğe Kaydı
dc.contributor.authorKonstas, Anastasios G. P.
dc.contributor.authorQuaranta, Luciano
dc.contributor.authorBozkurt, Banu
dc.contributor.authorKatsanos, Andreas
dc.contributor.authorGarcia-Feijoo, Julian
dc.contributor.authorRossetti, Luca
dc.contributor.authorShaarawy, Tarek
dc.date.accessioned2020-03-26T19:22:54Z
dc.date.available2020-03-26T19:22:54Z
dc.date.issued2016
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractCurrent management of glaucoma entails the medical, laser, or surgical reduction of intraocular pressure (IOP) to a predetermined level of target IOP, which is commensurate with either stability or delayed progression of visual loss. In the published literature, the hypothesis is often made that IOP control implies a single IOP measurement over time. Although the follow-up of glaucoma patients with single IOP measurements is quick and convenient, such measurements often do not adequately reflect the untreated IOP characteristics, or indeed the quality of treated IOP control during the 24-h cycle. Since glaucoma is a 24-h disease and the damaging effect of elevated IOP is continuous, it is logical that we should aim to understand the efficacy of all treatment options throughout the 24-h period. This article first reviews the concept and value of diurnal and 24-h IOP monitoring. It then critically evaluates selected available evidence on the 24-h efficacy of medical, laser and surgical therapy options. During the past decade several controlled trials have significantly enhanced our understanding on the 24-h efficacy of all glaucoma therapy options. Nevertheless, more long-term evidence is needed to better evaluate the 24-h efficacy of glaucoma therapy and the precise impact of IOP characteristics on glaucomatous progression and visual prognosis.en_US
dc.description.sponsorshipAlconNovartis; Deva; Santen; Laboratoires Thea; AllerganAllergan; PfizerPfizer; Sylentis; Bausch and Lomb; Opko; Glaukos; Ivantis; Istar; InnFocus; Transcend; Sensimed; Centervue; MSD; NovartisNovartis; Omikron; Sifi; Visufarmaen_US
dc.description.sponsorshipAnastasios G. P. Konstas has received honorariums from (and is a consultant for): Alcon, Allergan and Santen. Luciano Quaranta has received honorariums from (and is a consultant for): Alcon, Allergan, Santen, SOOFT and Visufarma. Banu Bozkurt has received honorariums from (and is a consultant for) Allergan and had congress and travel expenses covered by Alcon and Deva. Andreas Katsanos has received honorariums from Santen and had congress and travel expenses covered by Alcon, Santen and Laboratoires Thea. Julian Garcia-Feijoo is an advisor for Alcon, Bausch and Lomb, Opko, Ivantis and Istar and has received educational grants from Santen. He has also received fees for trials sponsored by Alcon, Allergan, Pfizer, Sylentis, Bausch and Lomb, Santen, Opko, Glaukos, Ivantis, Istar, InnFocus, Transcend and Sensimed. Luca Rossetti has received travel grants and honorariums from (and is a consultant for): Allergan, Bausch and Lomb, Centervue, MSD, Novartis, Omikron, Santen, Sifi and Visufarma. Tarek Shaarawy has no disclosures to report. Norbert Pfeiffer has received honorariums (and is a consultant for): Alcon, Allergan and Santen. Stefano Miglior has received honorariums from Allergan, SIFI, Alcon, Dorr and had congress and travel expenses covered by Allergan, SIFI and Alcon.en_US
dc.identifier.doi10.1007/s12325-016-0302-0en_US
dc.identifier.endpage517en_US
dc.identifier.issn0741-238Xen_US
dc.identifier.issn1865-8652en_US
dc.identifier.issue4en_US
dc.identifier.pmid26909513en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage481en_US
dc.identifier.urihttps://dx.doi.org/10.1007/s12325-016-0302-0
dc.identifier.urihttps://hdl.handle.net/20.500.12395/33168
dc.identifier.volume33en_US
dc.identifier.wosWOS:000374992100001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSPRINGERen_US
dc.relation.ispartofADVANCES IN THERAPYen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subject24-h efficacyen_US
dc.subject24-h intraocular pressure controlen_US
dc.subjectCircadian intraocular pressure characteristicsen_US
dc.subjectDiurnal intraocular pressureen_US
dc.subjectGlaucoma therapy optionsen_US
dc.subjectIntraocular pressure monitoringen_US
dc.subjectOphthalmologyen_US
dc.title24-h Efficacy of Glaucoma Treatment Optionsen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu